Proof of concept for SNBL's intranasal granisetron
This article was originally published in Scrip
Executive Summary
Shin Nippon Biomedical Laboratories (SNBL) is claiming proof of concept for its novel intranasal form of granisetron following positive Phase II results, which the company expects will add value to the product and aid out-licensing discussions.